Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKN-028 in AML
NCT01573247Phase 2Terminated
- Sponsor
- Akinion Pharmaceuticals AB
- Start
- Dec 2011
- Primary completion
- Mar 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of AKN-028 in acute myeloid leukemia (AML), sponsored by Akinion Pharmaceuticals AB. Started Dec 2011; status: terminated.
02
Drugs
AKN-028
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01573247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573247.